FierceBiotech  Jun 8  Comment 
Novo Nordisk's next big thing in diabetes beat out the world's top-selling insulin in a late-stage trial, stoking blockbuster hopes for the combination treatment. But a previous regulatory setback will keep the cocktail off of U.S. shelves until...
Reuters  Jun 1  Comment 
The sale of Portugal's Novo Banco is likely to end with a duel between two Chinese bidders, which have both presented offers of just over 4 billion euros ($4.4 billion),...
Motley Fool  May 23  Comment 
Big Pharma suspected that MannKind's Afrezza would make its way to the market eventually. Now that its here, what does the industry have in its pipeline that could potentially slow adoption?
FierceBiotech  May 21  Comment 
Novo Nordisk, gradually exiting the world of autoimmune R&D, has found a home for one of its former projects, handing a development program over to Johnson & Johnson for an undisclosed sum.
GenEng News  May 21  Comment 
Johnson & Johnson’s Janssen Biotech has acquired from Novo Nordisk a development program focused on autoimmune diseases. The price was not disclosed. Novo, which announced the deal yesterday, said in a statement it sold an exclusive global...
FiercePharma  May 21  Comment 
Baxter said back in March that Novo Nordisk's recently launched hemophilia med infringed some of its patents, spurring an investigation from the U.S. International Trade Commission. But the Danish drugmaker doesn't see what all the fuss is about.
Jutia Group  May 20  Comment 
[Reuters] - Novo Nordisk on Wednesday rejected claims by Baxter International that its drug used substances developed by the U.S. rival, following the launch this week of a U.S. investigation into possible patent infringement. Baxter said in March...
FierceBiotech  May 18  Comment 
The commercial potential of NASH, a common liver disease with no approved treatments, has seemingly launched a thousand R&D ships around the industry. And Novo Nordisk, emboldened by an investigator-sponsored study, might be sitting on an...

You may also be interested in articles related to Novo Nordisk A/S (NVO):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki